CD73: a new biomarker in triple-negative breast cancer - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Translational Cancer Research Année : 2018

CD73: a new biomarker in triple-negative breast cancer

Résumé

Triple-negative breast cancer (TNBC) constitute 10–20% of all breast cancers and are characterized by the lack of hormone receptors (estrogen and progesterone receptors) and HER2/neu expression (1). TNBC are not eligible to hormonotherapy and Herceptin/trastuzumab targeted therapy and are generally associated with poor clinical outcome (2). Anthracycline/taxane-based neoadjuvant chemotherapy is the primary systemic treatment but resistance to this treatment is common and the identification of new potential therapeutic molecules is required to improve the outcome of TNBC patients.

Dates et versions

hal-02289836 , version 1 (17-09-2019)

Identifiants

Citer

Virginie Lafont, Henri-Alexandre Michaud, Nathalie Bonnefoy. CD73: a new biomarker in triple-negative breast cancer. Translational Cancer Research, 2018, 7 (S5), pp.S594-S596. ⟨10.21037/tcr.2018.05.22⟩. ⟨hal-02289836⟩
33 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More